Evidence map›Paper›PMID 42457306›Full record

Trial reportThe Indian journal of tuberculosis2026

Patient experiences and motivations in tuberculosis treatment: Insights from a digital adherence technology trial.

Sarah Iribarren, Javier Roberti, Alfie Aguilar-Vidrio, Barry Lutz, Fernando Rubinstein

Abstract readMulticenter StudyPragmatic Clinical Trial
In one paragraph

Trial report in The Indian journal of tuberculosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah IribarrenUniversity of Washington School of Nursing, Seattle, USA.
Javier RobertiCIESP/CONICET, Buenos Aires, Argentina; Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina. Electronic address: jroberti@iecs.org.ar.
Alfie Aguilar-VidrioUniversity of Washington School of Nursing, Seattle, USA.
Barry LutzUniversity of Washington Department of Bioengineering, Seattle, USA.
Fernando RubinsteinInstitute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Funding

TB-TST (TB treatment support tools): Refinement and evaluation of an interactive mobile app and direct adherence monitoring on TB treatment outcomesR01AI147129 · NIAID · INSTITUTO DE EFECTIVIDAD CLINICA Y SANIT · PI IRIBARREN, SARAH JO HANNAH, RUBINSTEIN, FERNANDO ADRIÁN · 2019 to 2023
$2.3M
NIAID NIH HHS R01 AI147129
6 · The paper itself

Abstract

Non-adherence to Tuberculosis (TB) treatment remains a global health challenge, particularly in low- and middle-income countries. Digital Adherence Technologies (DATs) have shown promise in improving treatment outcomes, yet little is known about user perceptions. Through an exit survey, this study evaluated the acceptability to participants of the Tuberculosis Treatment Support Tools intervention, which combines a mobile app for reporting of medication, direct contact with healthcare team, and a metabolite test to support self-administered TB treatment in Argentina. A pragmatic clinical trial was conducted at four public hospitals in Buenos Aires, in which 80 participants completed exit surveys. The app was rated highly for ease of use (4.3/5) and was strongly recommended to others (4.7/5). Features like medication reminders, direct messaging with treatment supporters, and an anonymous patient forum were praised for enhancing adherence and reducing isolation. The metabolite test, generally well-received, faced minor usability challenges. Participants highlighted need for simplified reporting and improved reminders. Motivation for adherence stemmed from health improvement goals, family support, and professional guidance. Recommendations for improvement included personalized features and addressing technical barriers. The intervention demonstrates potential for enhancing adherence by meeting practical and emotional needs, offering insights for the refinement of digital tools in TB treatment care.

Indexed as

Antitubercular AgentsMedication AdherenceMobile ApplicationsMotivationTuberculosisAdherence InterventionsAdultArgentinaDigital HealthFemaleHumansMaleMiddle AgedReminder SystemsAntitubercular AgentsDigital Adherence Technologies (DATs)Mobile Health (mHealth) applicationsPatient-centered designTuberculosis (TB) treatment adherence

Identifiers

PMID42457306
PMCPMC13663146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.